RAYOS
Clinical safety rating: caution
Comprehensive clinical and safety monograph for RAYOS (RAYOS).
Synthetic glucocorticoid with anti-inflammatory, immunosuppressive, and metabolic effects; binds to glucocorticoid receptor, modulating gene expression and inhibiting phospholipase A2, cytokine production, and immune cell activity.
| Metabolism | Hepatic via CYP3A4; prednisolone is the active metabolite; undergoes glucuronidation and sulfation; excreted in urine. |
| Excretion | Renal: ~80% as inactive metabolites; fecal: ~5%; biliary: small amount. |
| Half-life | 2-3 hours (terminal); prolonged in hepatic impairment; circadian-timed formulation intended for once-daily morning dosing. |
| Protein binding | 90-95% bound to corticosteroid-binding globulin (CBG) and albumin. |
| Volume of Distribution | Vd ~0.5 L/kg; reflects moderate tissue distribution. |
| Bioavailability | Oral: ~80% (immediate-release); overall ~100% relative to prednisolone; decreased by food. |
| Onset of Action | Oral (immediate-release component): ~1 hour; oral (delayed-release component): variable but designed for morning cortisol peak. |
| Duration of Action | 24 hours (due to delayed-release and immediate-release combination providing sustained effect); clinical duration depends on dose and disease. |
| Molecular Weight | 358.43 |
Initial adult dose 5-60 mg orally once daily, adjusted based on disease severity and response. Typically administered as a single dose in the morning with food.
| Dosage form | TABLET, DELAYED RELEASE |
| Renal impairment | No specific dose adjustment required for renal impairment. Monitor for fluid retention and electrolyte disturbances. |
| Liver impairment | Child-Pugh Class A: no adjustment; Child-Pugh Class B or C: reduce dose by 50% and titrate cautiously. |
| Pediatric use | Weight-based: 0.14-2 mg/kg/day orally divided every 12-24 hours, not to exceed 60 mg/day. Titrate to lowest effective dose. |
| Geriatric use | Initiate at low end of dosing range (e.g., 5 mg/day) due to increased risk of osteoporosis, hyperglycemia, and immunosuppression. Monitor for adverse effects. |
| 1st trimester | Prednisone is a corticosteroid; first-trimester use is associated with a small increased risk of oral clefts (odds ratio ~3.4). Benefit-risk assessment required; avoid if possible. |
| 2nd trimester | Use may increase risk of preterm birth, low birth weight, and maternal glucose intolerance. Monitor for gestational diabetes. |
| 3rd trimester | Prolonged use may lead to fetal adrenal suppression. Taper if used near term. Avoid high doses during delivery. |
Clinical note
Comprehensive clinical and safety monograph for RAYOS (RAYOS).
| Placental transfer | Prednisone crosses the placenta; about 10% of maternal dose reaches fetus. It is converted to prednisolone, which has higher activity. |
| Breastfeeding | Prednisone enters breast milk in low concentrations (<10% of maternal dose). With maternal doses up to 80 mg/day, amounts ingested by infant are minimal. No adverse effects reported. However, monitor infant for adrenal suppression if mother on high doses long-term. Advise to wait 4 hours after dose before nursing to reduce exposure. |
■ FDA Black Box Warning
None.
| Serious Effects |
Systemic fungal infectionsHypersensitivity to prednisone or any componentAdministration of live or live-attenuated vaccinesIdiopathic thrombocytopenic purpura (ITP) - avoid for treatment (but not absolute contraindication for all uses)
| Precautions | Increased risk of infections due to immunosuppression; avoid live vaccines., Hypothalamic-pituitary-adrenal (HPA) axis suppression with prolonged use; taper dose gradually., May exacerbate systemic fungal infections; use caution in patients with latent tuberculosis or viral infections., Monitor for corticosteroid-induced hyperglycemia, hypertension, osteoporosis, and cataract formation., May mask signs of infection or worsen existing infections. |
| Food/Dietary | Take with food to ensure proper delayed release. Avoid grapefruit juice due to potential CYP3A4 inhibition increasing prednisone levels. Limit high-sodium foods to reduce fluid retention. Monitor potassium intake as prednisone may cause hypokalemia. |
Loading safety data…
| Lactation Rating | L2 (Safe) |
| Teratogenic Risk | Pregnancy Category C: Corticosteroids cross placenta. First trimester: Increased risk of cleft palate (odds ratio 3.4). Second/third trimester: Fetal adrenal suppression, intrauterine growth restriction, preterm delivery. Risk proportional to dose and duration. |
| Fetal Monitoring | Maternal: Blood pressure, blood glucose, signs of infection, adrenal suppression. Fetal: Serial growth ultrasound (every 4 weeks) for growth restriction; fetal heart rate monitoring if preeclampsia or preterm labor signs. |
| Fertility Effects | Corticosteroids may suppress HPA axis and inhibit ovulation; reversible upon dose reduction or discontinuation. Sometimes used as adjunct in infertility conditions (e.g., autoimmune), but no direct toxicity to gametes. |
| Clinical Pearls | RAYOS (prednisone) delayed-release tablets are designed to release prednisone approximately 4 hours after ingestion, aligning with the circadian rhythm of inflammation. Administer with food to ensure consistent delayed release. Do not crush or chew tablets. Monitor for adrenal suppression, especially during stress or after long-term use. |
| Patient Advice | Take RAYOS once daily with food, at the same time each day. · Swallow the tablet whole; do not crush, chew, or break it. · Do not stop taking RAYOS abruptly without consulting your doctor, as it may cause withdrawal symptoms. · Avoid grapefruit juice as it may affect prednisone metabolism. · Report any signs of infection, sudden weight gain, or mood changes to your healthcare provider. |